Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer-Reference-Cited by-同舟云学术

Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer

Published:2019-11 Issue:5 Volume:76 Page:599-603
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Wang Li,Gong Yixuan,Saci Abdel,Szabo Peter M.,Martini Alberto,Necchi Andrea,Siefker-Radtke Arlene,Pal Sumanta,Plimack Elizabeth R.,Sfakianos John P.,Bhardwaj Nina,Horowitz Amir,Farkas Adam M.,Mulholland David,Fischer Bruce S.,Oh William K.,Sharma Padmanee,Zhu Jun,Galsky Matthew D.

Publisher

Elsevier BV

Subject

Urology

Reference11 articles.

1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet (London, England),2016

2. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial;Sharma;Lancet Oncol,2017

3. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer;Sweis;Cancer Immunol Res,2016

4. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells;Mariathasan;Nature,2018

5. An FGFR3/MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers;Mahe;EMBO Mol Med,2018

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision oncology targeting FGFRs: A systematic review on pre-clinical activity and clinical outcomes of pemigatinib;Critical Reviews in Oncology/Hematology;2024-10

2. Biomarkers of prostate bladder and testicular cancers: current use in anatomic pathology and future directions;Surgical and Experimental Pathology;2024-08-20

3. FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies;Cancer Communications;2024-08-19

4. The Role of Fibroblast Growth Factor Receptors Inhibitors in Bladder Cancer;Journal of Urologic Oncology;2024-07-31

5. Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma;Pharmacological Research;2024-07